Bio-Techne (TECH) EBIT (2009 - 2026)

Bio-Techne has reported EBIT for 18 years, with the latest figure at $75.5 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 95.04% year-over-year to $75.5 million; the trailing twelve-month figure through Mar 2026 stood at $153.8 million (down 10.58% YoY), and the FY2025 full-year result was $102.3 million, down 50.53% from the prior year.
• EBIT for Q1 2026 stood at $75.5 million, up from $54.5 million in the prior quarter.
• The five-year high for EBIT was $94.5 million in Q2 2023, with the low at -$23.9 million in Q2 2025.
• Average EBIT over 5 years is $56.3 million, with a median of $55.9 million recorded in 2023.
• Year-over-year, EBIT tumbled 152.07% in 2025 and jumped 95.04% in 2026.
• Tracing TECH's EBIT over 5 years: stood at $67.9 million in 2022, then tumbled by 44.02% to $38.0 million in 2023, then increased by 24.77% to $47.4 million in 2024, then climbed by 14.85% to $54.5 million in 2025, then soared by 38.62% to $75.5 million in 2026.
• The last three EBIT figures came in at $75.5 million (Q1 2026), $54.5 million (Q4 2025), and $47.7 million (Q3 2025), per Business Quant data.

Peer Comparison